<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02957630</url>
  </required_header>
  <id_info>
    <org_study_id>MIT-Es0001-C201</org_study_id>
    <secondary_id>2016-001316-37</secondary_id>
    <nct_id>NCT02957630</nct_id>
  </id_info>
  <brief_title>&quot;E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study&quot;</brief_title>
  <official_title>A Single Center, Randomized,Open-label,Controlled, Three-arm Study to Evaluate the Effect of a New Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and of Two Reference COCs Containing Either 30 mcg Ethinylestradiol (EE) and 150 mcg Levonorgestrel (LNG) or 20 mcg EE and 3 mg DRSP on Endocrine Function, Metabolic Control and Hemostasis During 6 Treatment Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Estetra</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Estetra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will provide an assessment of the effect of this combination on endocrine
      function, metabolic control and hemostasis during 6 treatment cycles. This will be compared
      to the effects of two reference COCs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">October 9, 2017</completion_date>
  <primary_completion_date type="Actual">October 9, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of prothrombin fragment 1+2</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of APC resistance (ETP-based, APTT-based)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of D-dimer</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of factor VII</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of factor VIII</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of von Willebrand factor</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of factor II</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of antithrombin</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of free and total Protein S</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of protein C</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of plasminogen activator inhibitor type-1 (PAI-1)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of tissue type plasminogen activator (t-PA)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of plasminogen</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of free tissue factor pathway inhibitor (TPFI)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of E-selectin</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of fibrinogen</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of insulin</measure>
    <time_frame>At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of glucose</measure>
    <time_frame>At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of C-peptide</measure>
    <time_frame>At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of glycated hemoglobin (HbA1c)</measure>
    <time_frame>At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Homeostasis Model Assessment - Insulin Resistance (HOMA-IR)</measure>
    <time_frame>At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral glucose tolerance test (OGTT)</measure>
    <time_frame>At 0 (pre-glucose challenge), 30, 60, 90, 120 and 180 minutes after glucose challenge during pretreatment Cycle; at 0 (pre-glucose challenge), 30, 60, 90, 120 and 180 minutes after glucose challenge during Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of prolactin</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of follicle-stimulating hormone (FSH)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of luteinizing hormone (LH)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of estradiol (E2)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of progesterone (P)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of thyro√Ød stimulating hormone (TSH)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of free thyroxine (fT3)/free triiodothyronine (fT4)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of dihydroepiandrostenedione (DHEAS)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of androstenedione</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of total testosterone (T)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of dihydrotestosterone (DHT)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of total cortisol</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of aldosterone</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of high density lipoprotein (HDL)-cholesterol</measure>
    <time_frame>At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of low density lipoprotein (LDL)-cholesterol</measure>
    <time_frame>At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of total cholesterol</measure>
    <time_frame>At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of triglycerides</measure>
    <time_frame>At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of lipoprotein (a)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of apoliporotein A1</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of apoliporotein B</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of C-reactive protein</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of corticosteroid binding globulin (CBG)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of sex hormone binding globulin (SHBG)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of thyroxin binding globulin (TBG)</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of angiotensinogen</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability</measure>
    <time_frame>From up to 28 days before randomization to maximum Day 4 of the Cycle 7 (1 cycle = 28 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of lactate dehydrogenase (LDH) 1 and 2</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle and between Days 18 and 21 for the Cycle 6 (1 cycle = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of tropinin T and I</measure>
    <time_frame>Between Days 18 and 21 for the pretreatment Cycle and between Days 18 and 21 for the Cycle 6 (1 cycle = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG) parameters</measure>
    <time_frame>At screening and between Days 18 and 21 for Cycle 6 (1 cycle = 28 days).</time_frame>
    <description>The following ECG parameters will be recorded: heart rate, PR-interval, QRS-duration, QT-interval, QTc interval (Fridericias's)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters</measure>
    <time_frame>At screening and between Days 18 and 21 for Cycle 6 (1 cycle = 28 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to end of treatment in the different items of the menstrual distress questionnaires (MDQ) form C</measure>
    <time_frame>At pretreatment Cycle and between Days 18 and 21 for Cycle 6 (1 cycle = 28 days).</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Contraception</condition>
  <condition>Liver Metabolism</condition>
  <condition>Hemostasis Parameter</condition>
  <arm_group>
    <arm_group_label>15 mg E4/3 mg DRSP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg estetrol/3 mg drospirenone combined oral contraceptive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mcg EE/150 mcg LNG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mcg ethinylestradiol/150 mcg levonorgestrel combined oral contraceptive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mcg EE/3 mg DRSP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mcg ethinylestradiol/3 mg drospirenone combined oral contraceptive</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 mg E4/3 mg DRSP</intervention_name>
    <description>15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.</description>
    <arm_group_label>15 mg E4/3 mg DRSP</arm_group_label>
    <other_name>15 mg estetrol and 3 mg drospirenone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mcg EE/150 mcg LNG</intervention_name>
    <description>30 mcg EE combined with 150 mcg LNG administered in a 21/7‚Äëday regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.</description>
    <arm_group_label>30 mcg EE/150 mcg LNG</arm_group_label>
    <other_name>30 mcg ethinylestradiol and 150 mcg levonorgestrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mcg EE/3 mg DRSP</intervention_name>
    <description>20 mcg EE combined with 3 mg DRSP administered in a 24/4‚Äëday regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.</description>
    <arm_group_label>20 mcg EE/3 mg DRSP</arm_group_label>
    <other_name>20 mcg ethinylestradiol and 3 mg drospirenone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult woman

          -  Negative pregnancy test at subject screening and randomization

          -  Aged 18-50 years (inclusive) at the time of signing the ICF

          -  Good physical and mental health on the basis of medical, surgical and gynecological
             history, physical examination, gynecological examination, clinical laboratory, ECG,
             echocardiography and vital signs

          -  BMI from 18.0 to 30.0 kg/m¬≤, inclusive, at time of screening visit

          -  Able to fulfil the requirements of the protocol and have indicated a willingness to
             participate in the study by providing written informed consent

        Exclusion Criteria:

          -  Known hypersensitivity to any of the investigational product ingredients

          -  Smoking if &gt; 35 years old

          -  Dyslipoproteinemia or use of antilipidemic agent

          -  Known diabetes mellitus

          -  Current use of antidiabetic drugs, including insulin

          -  Arterial hypertension

          -  Any condition associated with an increased risk of venous thromboembolism and/or
             arterial thromboembolism.

          -  Any condition associated with abnormal uterine/vaginal bleeding.

          -  Presence of an undiagnosed breast mass

          -  Current symptomatic gallbladder disease

          -  History of pregnancy- or COC-related cholestasis

          -  Presence or history of severe hepatic disease

          -  Presence or history of pancreatitis if associated with hypertriglyceridemia

          -  Porphyria

          -  Presence or history of benign liver tumors (focal nodular hyperplasia and
             hepatocellular adenoma)

          -  Presence of renal impairment (glomerular filtration rate [GFR] &lt;60 mL/min/1.73m¬≤)

          -  Hyperkalemia or presence of conditions that predispose to hyperkalemia

          -  Presence or history of hormone-related malignancy

          -  History of non-hormone-related malignancy within 5 years before screening; subjects
             with a non-melanoma skin cancer are allowed in the study

          -  Use of drugs potentially triggering interactions with COCs

          -  History of alcohol or drug abuse within 12 months prior to screening

          -  Presence or history of thyroid disorders

          -  Participation in another investigational drug clinical study within 1 month (30 days)
             or have received an investigational drug within the last 3 months (90 days) prior to
             randomization. Subjects who participated in an oral contraceptive clinical study using
             Food and Drug Administration (FDA)/European Union (EU) approved active ingredients,
             may be randomized 2 months (60 days) after completing the preceding study

          -  Sponsor, contract research organization (CRO) or Principal Investigator's (PI's) site
             personnel directly affiliated with this study

          -  Is judged by the PI to be unsuitable for any reason
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Klipping</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dinox BV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dinox BV</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Estetrol (E4)</keyword>
  <keyword>Drospirenone (DRSP)</keyword>
  <keyword>Ethinylestradiol (EE)</keyword>
  <keyword>Levonorgestrel (LNG)</keyword>
  <keyword>Oral contraceptive</keyword>
  <keyword>Prevention of pregnancy</keyword>
  <keyword>Hemostasis</keyword>
  <keyword>Metabolism</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Hemostatics</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

